Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression

Tatiana V. Kulding, James H.A. Clubb, Dafne C.A. Quixabera, Joao M. Santos, Riikka Havunen, Alexander Kononov, Camilla Heinio, Victor Cervera-Carrasco, Santeri Pakola, Saru Basnet, Susanna Gronberg-Vahä-Koskela, Victor Arias, Ivan Gladwyn-Ngo, Katri Aro, Leif Bäck, Jari Räsänen, Ilkka Ikonen, Kristian Borenius, Mikko Räsänen, Otto Hemminki, Antti Rannikko, Anna Kanerva, Johanna Tapper, and Akseli Hemminki

Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland; TILT Bioterapeutics Ltd, Helsinki, Finland; Systems Oncology Group, Cancer research UK, Manchester University, Manchester, UK; Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland; Taconic Biosciences GmbH, Leverkusen, Germany; Department of Ototorhinolaryngology – Head and Neck Surgery, Helsinki Head and Neck Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Urology, Helsinki University Hospital, Helsinki, Finland; Department of Gynecology and Obstetrics, Helsinki University Hospital, Helsinki, Finland

ABSTRACT

Cytokines have proven to be effective for cancer therapy, however whilst low-dose monotherapy with cytokines provides limited therapeutic benefit, high-dose treatment can lead to a number of adverse events. Interleukin 7 has shown promising results in clinical trials, but anti-cancer effect was limited, in part due to a low concentration of the cytokine within the tumor. We hypothesized that arming an oncolytic adenovirus with Interleukin 7, enabling high expression localized to the tumor microenvironment, would overcome systemic delivery issues and improve therapeutic efficacy. We evaluated the effects of Ad5/3-E2F-d24-hIL7 (TILT-517) on tumor growth, immune cell activation and cytokine profiles in the tumor microenvironment using three clinically relevant animal models and ex vivo tumor cultures. Our data showed that local treatment of tumor bearing animals with Ad5/3-E2F-d24-hIL7 significantly decreased cancer growth and increased frequency of tumor-infiltrating cells. Ad5/3-E2F-d24-hIL7 promoted notable upregulation of pro-inflammatory cytokines, and concomitant activation and migration of CD4+ and CD8+ T cells. Interleukin 7 expression within the tumor was positively correlated with increased number of cytotoxic CD4+ cells and IFNγ-producing CD4+ and CD8+ cells. These findings offer an approach to overcome the current limitations of conventional IL7 therapy and could therefore be translated to the clinic.

Introduction

Cytokines are small protein molecules that provide growth, differentiation, and inflammatory or anti-inflammatory signals to different cell types. Cytokine immunotherapy is an appealing approach for treating cancer patients with advanced malignancies because signals transduced via cytokines activate the host immune system, making it more efficient in the recognition and elimination of cancer cells. However, to date, only two cytokines – interleukin 2 (IL2) and interferon-alpha – are approved by the U.S. Food and Drug Administration for cancer treatment.1,2 Both of them can stimulate the proliferation and activation of T cells, but high concentrations are needed to achieve therapeutic efficacy in cancer patients. Consequently, increasing the systemic dose results in adverse events before sufficient tumor concentrations can be reached.3–5

Interleukin 7 (IL7) is one of the key cytokines involved in immune cell expansion and proliferation. Its main function is to maintain the survival and diversity of naïve and memory T cells.6,7 IL7 can improve the effector functions of T cells via repression of negative regulators of T cell activation and increase interferon gamma (IFNg) production.8 Conversely, IL7 antagonizes the immunosuppressive pathways via several mechanisms. It prevents the activation of regulatory T cells (Tregs) and inhibits their ability to suppress effector cells.9 Further, IL7 abrogates inhibition of CD8 + T cell proliferation and prevents their exhaustion.10,11

Possessing multiple immune-enhancing features, IL7 is an attractive cytokine for immunotherapy. In contrast to IL2 and interferon-alpha, it showed a reasonable safety profile in phase I clinical trials, even at the highest studied dose.12 Moreover, IL7 treatment leads to a remarkable increase in circulating CD4+ and CD8 + T cells, both naive and memory; however, no effect on tumor progression and overall survival of cancer patients was observed in these studies.13 One possible reason is the inability to reach sufficient concentrations of IL7 within the tumor with systemic delivery. Thus, recent studies describe new approaches for IL7 delivery, including IL7 fusion proteins...
able to circulate longer in vivo, and engineered immune cells constitutively expressing IL7. However, these technologies are still in the developmental stage, so it remains unclear if they will be safe and effective in the clinic.

In this study, we developed an oncolytic adenovirus coding for the full length human IL7 sequence – Ad5/3-E2F-d24-hIL7 (TILT-517). It combines the capability to maintain high concentrations of IL7 in the tumor microenvironment with the inherent ability of adenovirus to stimulate an immune response. Together this can lead to increased immune cell infiltration to the tumor and activation of antiviral signaling pathways, converting the local microenvironment from an immunosuppressive to an immunostimulatory one. Moreover, since Ad5/3-E2F-d24-hIL7 is modified to replicate specifically in malignant cells, this approach enables effective oncolysis of cancer cells and reduced probability of adverse off-target effects of the treatment.

In the last two years, there has been increased efforts to develop oncolytic viruses armed with IL7. One study highlighted the antitumor activity of an oncolytic vaccinia virus encoding IL7 and IL12 in both injected and non-injected tumors, through immune status changes in humanized mice bearing human cancer cells. Another study described the benefits of using IL7 loaded oncolytic adenovirus in combination with CAR-T in glioblastoma, enabling survival and therapeutic efficacy of the cells. However, chimeric oncolytic adenoviruses armed with IL7 as a monotherapy have not been studied. In this paper, we describe lytic and immune-enhancing features of the virus in several preclinical models shedding the light on its potential for translation to the clinic.

Methods

Cell lines

Human cancer cell lines A549 (lung adenocarcinoma) and RD (rhabdomyosarcoma) were purchased from the American Type Culture Collection (ATCC) (Manassas, USA). The Syrian hamster cancer cell line DDT1-MF2 (leiomyosarcoma) was a kind gift from Dr. William Wold, hamster HapT1 (pancreatic ductal adenocarcinoma) was obtained from Leibniz Institute (DSMZ, Braunschweig, Germany), hamster HT100 (lung adenocarcinoma) was obtained from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan). All cell lines were cultured under recommended conditions.

Virus construction

The Ad5/3-E2F-d24-hIL7 virus has been constructed by a previously described technique. Tumor-specific replication was achieved by two modifications: an E2F promoter and a 24-base pair deletion in the constant region of E1A, which determines tumor selectivity regarding viral replication. Human IL7 (hIL7) coding sequence (Genbank: NP_000871.1) was introduced in E3 region replacing gp19k and 6.7k genes via bacterial artificial chromosome (BAC) recombineering strategy. The resulting viral vector sequence was confirmed by next generation sequencing.

Viral particles were produced via cesium chloride gradient centrifugation, and the infectivity and concentration of the resulting virus were determined by TCID50 assay according to a protocol described elsewhere.

Cell viability assay

Human cell lines A549 and RD were plated in 96-well plates (flat bottom) in triplicates at 1 × 10^4 cells/well for 24 hours and infected with 1, 10, 100 or 1000 VP/cell of either Ad5/3-E2F-d24 virus (also referred in the text as backbone or unarmed backbone), or Ad5/3-E2F-d24-hIL7 (also referred in the text as IL7 virus). Similarly, hamster cell lines HT100, DDT1-MF2 and HapT1 were plated in triplicates at 1 × 10^4 cells/well for 24 hours and infected with 100, 1000, 5000 or 10000 VP/cell of either backbone virus, or Ad5/3-E2F-d24-hIL7.

Cell viability was measured after 4 days (A549 and RD), 5 days (HT100 and DDT1-MF2) or 8 days (HapT1) by incubating cells for 2 hours with 20% of CellTiter 96 AQueous One Solution Proliferation Assay reagent (Promega, Wisconsin, USA). Absorbance was read at 490 nm using Hidex Sense plate reader (Hidex, Turku, Finland). Data were normalized to the uninfected mock control group.

Cytokine expression and bioactivity assay

The aforementioned human and hamster cell lines were infected with either 1000 VP/cell (A549 and RD) or 10000 VP/cell (HT100 and DDT1-MF2) of Ad5/3-E2F-d24-hIL7 for 3 days. Human IL7 concentration was measured from cell culture supernatants using the BD Cytometric Bead Array Human Soluble Protein Master Buffer Kit (BD Biosciences, New Jersey, USA) together with human IL7 Flex Set (BD Biosciences, New Jersey, USA) according to the manufacturer’s instructions. The beads were detected with the BD Accuri Flow Cytometer and the results were analyzed with FCAP Array software (version 3.0.1; BD Biosciences, New Jersey, USA).

To confirm that virally produced hIL7 was bioactive, murine IL7-dependent cell line 2E8 (ATCC, Virginia, USA) was cultured in triplicates at 2.5 × 10^5 cells/ml in McCoy’s 5A media (ThermoFisher, Massachusetts, USA) supplemented with 10% FBS, 1% L-glutamine and 1% Pen/strep for 24 hours. Supernatant from A549 cells infected with Ad5/3-E2F-d24-hIL7 was filtered to remove infectious virus particles and was added at 1:1, 1:4, 1:16, 1:64 and 1:256 dilutions and incubated for 5 days prior to viability assay using 20% of CellTiter 96 AQueous One Solution Proliferation Assay reagent as described above. Recombinant murine and human IL7 were used at 20 ng/ml concentration as positive controls.

IL7 cross-reactivity assay

Hamster splenocytes were seeded in 96-well plates (U-bottom) in triplicates at 2.5 × 10^5 cells/well for 24 hours to investigate if hamster immune cells cross-react to human IL7. Then the cells were stimulated with either Concanavalin A (ConA), or ConA in combination with recombinant hIL7 (Peprotech, New Jersey, USA) for 5 days. Unstimulated cells were used as
a negative control, while cells stimulated with ConA and recombinant hIL2 (Peprotech, New Jersey, USA) were used as a positive control. On day 5, the viability test was performed using 20% of CellTiter 96 AQueous One Solution Proliferation Assay reagent as described above.

**Syngeneic hamster experimental model**

HapT1 tumors (2x10^6 cells) were engrafted subcutaneously in 5 weeks old male Syrian golden hamsters’ (*Mesocricetus auratus*) (Envigo, Indiana, USA) right flank. After tumors reached 5 to 6 mm in diameter, animals were randomized and treated intratumorally with 1 x 10^7 VP of either Ad5/3-E2F-d24 or Ad5/3-E2F-d24-hIL7 virus. Control animals received intratumoral injections of PBS. Tumors were measured every other day for 14 days with a digital caliper, and tumor volumes were calculated as (length x width^2)/2. Hamsters received a total of five rounds of virus treatment before they were euthanized on day 15, and their tumors were collected for subsequent analysis.

To study the toxicity of the virus, the aforementioned experiment was repeated, but animals were treated for 55 days with subsequent collection of lungs, hearts, livers, kidneys, and spleens for histopathological evaluation.

**Gene expression assay**

Fragments of animal tumor samples were preserved in RNA later (Sigma-Aldrich, Missouri, USA), and stored at -20°C until further use. RNA from the samples were isolated using RNeasy extraction kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions and RNA concentration was measured using Qubit4 Fluorometer (ThermoFisher, Massachusetts, USA). 250 ng of purified total RNA was used to synthesize cDNA with High capacity cDNA Reverse Transcription kit (ThermoFisher, Massachusetts, USA) according to the manufacturer’s instructions. Resulting cDNA was used for quantitative real-time PCR. The expression levels of Granzyme B, Perforin, CD25, CD137, IFNg, and PD1 were measured using the primers and probes listed in Supplementary table S1. The results were normalized against the content of hamster gamma actin housekeeping gene cDNA and against mock (ΔΔCt method). All PCR reactions were run in duplicates.

**Histopathology analysis**

Selected tissues (livers, lungs, hearts, spleens and kidneys) collected for histopathological analysis were fixed in 10% formalin, and routinely processed and paraffin embedded. Samples paraffin-blocks were sectioned into 5 mm thickness slides and further stained with hematoxylin and eosin. A veterinarian pathologist examined the samples slides in a blind manner.

**Patient samples processing and establishment of ex vivo tumor histocultures**

Fresh single-cell tumor digests were prepared from tumors using a protocol previously developed by our group. In brief, tumors were diced into small fragments and placed in a 50 mL falcon tube containing RPMI 1640 supplemented with 1% L-glutamine, 1% Pen/strep, collagenase type I (170 mg/L), collagenase type IV (170 mg/L), DNase I (25 mg/mL) and elastase (25 mg/mL) (all enzymes from Worthington Biochemical) for overnight enzymatic digestion with rocking at +37°C. After digestion, the cell suspension was filtered through a 70 μm filter and treated with ACK lysis buffer (Sigma-Aldrich, Missouri, USA) for the removal of undigested fragments and red blood cells. The resulting heterogeneous single-cell suspension was used to establish ex vivo tumor cultures by plating 3 x 10^5 viable cells in triplicates in a 96-well plate (U-bottom) and treating them with 100 VP/cell of either Ad5/3-E2F-d24 or Ad5/3-E2F-d24-hIL7 virus; uninfected cells were used as mock control. The cells were collected on day 3 in freezing media containing 90% fetal bovine serum (FBS) and 10% dimethyl sulfoxide and stored up to -140°C until further use for flow cytometry.

**Cytotoxicity and virus replication assay**

Cell viability of ex vivo tumor cultures was determined as described above. Briefly, cell viability was measured at days 3, 5 and 7 by incubating with 20% CellTiter 96 AQueous One Solution Proliferation Assay reagent for 2 hours. Data were normalized to uninfected control group.

In order to determine virus replication in ex vivo tumor cultures, the cells were collected in phosphate buffered saline on days 1, 2 and 3 after virus infection and the DNA was extracted with QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Virus presence was confirmed by quantitative real-time PCR targeting the E4 region using forward primer (5’-GGAGTGGCC CGGAGACAAC-3’), reverse primer (5’-ACTACGTC CGGCCGTCCCAT-3’) and probe (Fam-TGGCATGACACTA CGACCAACAGATCT-Tam). Quantification of E4 was calculated according to a standard curve generated using known concentrations of a viral DNA. The results were normalized to the content of human beta-actin housekeeping gene. All PCR reactions were run in duplicates.

**Chemokines and cytokines analysis**

Supernatants from the infected ex vivo tumor cultures were collected on day 3 and the presence of C-C motif ligand 2 (Ccl2), C-C motif ligand 5 (Ccl5), C-X-C motif chemokine 10 (Cxc10), interleukin 2 (IL2), tumor necrosis factor alpha (TNFa), IFNg, interferon 1 beta (IFN1b), interleukin 4 (IL4), interleukin 6 (IL6), interleukin 10 (IL10) and transforming growth factor beta (TGFb) was determined using the Essential Immune Response LEGENDplex panel (Biolegend, California, USA), according to the manufacturer’s instructions. The levels of C-X-C motif chemokine 9 (Cxc9; also known as MIG) and IL7 in supernatants were determined through human MIG and IL7 flex sets (BD Biosciences, New Jersey, USA) respectively. Samples were measured in triplicates using Accuri C6 flow cytometer and analyzed through either LEGENDplex Data Analysis Software Suite (Biolegend, California, USA) or FCAP Array software. The concentration of each analyte was
normalized to the total protein content measured via Qubit4 Fluorometer (ThermoFisher, Massachusetts, USA). This data was then normalized to uninfected control group.

**Migration assay**

Ex vivo tumor single cell suspensions were cultured at $3 \times 10^5$ viable cells in triplicates in a 96-well plate (U-bottom) using serum-free AIM-V media (ThermoFisher, Massachusetts, USA) and treated with either Ad5/3-E2F-d24 or Ad5/3-E2F-d24-hiL7 as described above. On day 3, supernatants were collected and plated in the bottom chamber of Transwell (Corning, New York, USA) with a 5 μM pore membrane. $5 \times 10^5$ PBMCs were added in the upper chamber and left for migration for 24 h.

After migration, the cells in the bottom chamber were stained with following antibodies: PE anti-human CD45, Alexa Fluor 700 anti-human CD3, V500 anti-human CD4, FITC anti-human CD8, PerCP-Cy5.5 anti-human CD56, APC anti-human CD14, APC-Cy7 anti-human CD11b, BV421 anti-human CD83 and PE-Texas Red anti-human CD206 (Supplementary table S2). Absolute cell count was performed using 123count eBeads (Invitrogen, Massachusetts, USA) according to the manufacturer’s recommendations. Samples were acquired in triplicates using FACS Aria II cell sorter (BD Biosciences, New Jersey, USA) collecting at least 50000 events per sample. Data analysis was performed using Flowjo software v10 (Flowjo LLC, BD Biosciences, New Jersey, USA).

**Cell sorting and RNA sequencing**

CD4+ and CD8 + T cells from ex vivo tumor cultures were labeled using following antibodies: FITC anti-human CD3 antibody (clone SK7, Biolegend, California, USA), PE anti-human CD8 antibody (clone SK1, Biolegend, California, USA) and PerCP-Cy5.5 anti-human CD4 antibody (clone RPA-T4, ThermoFisher, Massachusetts, USA). Sorting was performed on Sony SH800z sorter (SONY) using 100-μm microfluidic sorting chip with at least 90% purity.

RNA from the sorted cells was isolated using RNAqueous Micro Total RNA Isolation Kit (ThermoFisher, Massachusetts, USA) according to the manufacturer’s instructions, and measured with Qubit4 Fluorometer. Sequencing was performed by GENEWIZ (Germany) using PolyA selection and 20–30 million reads per sample. Comparison of gene expression between groups was performed using DESeq2, the Wald test was used to generate p-values and log2 fold changes. Genes with an adjusted p-value < 0.05 were called as differentially expressed genes.

**Human PBMC isolation and expansion**

Human PBMC isolation was performed through density gradient centrifugation with lymphoprep (StemCell technologies, Vancouver, Canada) according to the manufacturer’s recommendations.

PBMC expansion was carried out according to adjusted “rapid expansion” protocol published elsewhere. Briefly, $1 \times 10^7$ cells were placed into six-well G-rex culturing plates (Wilson Wolf, Minnesota, USA) filled with 30 mL of TIL medium (TM) containing RPMI 1640 supplemented with 20% FBS, 1% L-glutamine, 1% Pen/strep, 15 mM HEPES, 1 mM Na-pyruvate, 50 μM b-mercaptoethanol, 100 IU/mL recombinant human IL-2 (PeproTech, New Jersey, USA) and 50 ng/ml anti-human anti-CD3 antibody (clone OKT3, Invitrogen, Massachusetts, USA). Subsequently, the cells were incubated for 3 days in a humidified incubator at +37°C. At day 3, PBMCs were mixed with irradiated allogenic PBMCs at 1:200 ratio in 1:1 media (50% TM, 50% Rapid Expansion Media (REM), containing RPMI 1640 supplemented with 20% FBS, 1% L-glutamine, 1% Pen/strep and 100IU/mL recombinant human IL-2) and seeded to G-rex culturing plates at 2 × 10⁶ cells/well. After 5 days of incubation half of the media was replaced with fresh 1:1 TM and REM media. By day 7, half of the media was aspirated (while retaining the cells in the bottom) and the number of PBMCs was adjusted to 5 × 10⁶ cells/well every 3–4 days until day 14, in which PBMCs were collected in freezing medium and stored up to −140°C until further use.

**Generation of murine PDX ovarian cancer model (PDX-OvCa)**

A metastasis resected from the greater omentum of a patient bearing ovarian high-grade serous carcinoma stage IIIC was collected, digested and frozen, in accordance with previously described protocols. For the generation of a patient-derived xenograft (PDX), cells were thawed, resuspended in a 1:1 Matrigel/RPMI medium containing 1% P/S and 1% L-Glut and implanted in the lower lateral flanks of NOG mice (strain NOD.Cg-PrkdcscidIl2rgtm1Sug/JicTac, Taconic Biosciences GmbH, Leverkusen, Germany) (n = 3 with 2 tumors per mice). Animals were followed regularly for the development of tumors. Approximately, 6 months after the first engraftment, developed tumors were collected, processed as above and reimplanted into new NOG mice. In the second engraftment, tumors were harvested approximately 4 months later. Tumor samples were processed and cultured in vitro using 10% RPMI growth media until they started to grow normally. Cell were stored in freezing media at −80°C.

**PDX-OvCa murine experimental models (NOG and NOG-IL2)**

3 to 4 weeks old immunodeficient female NOG (strain NOD.Cg-PrkdcscidIl2rgtm1Sug/JicTac) and NOG-IL2 (strain NOD.Cg-PrkdcscidIl2rgtm1Sug Tg(CMV-IL2)4–2Jic/JicTac) mice were obtained from Taconic Biosciences GmbH, Leverkusen, Germany. Animals were engrafted subcutaneously in the lower lateral flank with 3.5 × 10⁶ PDX-OvCa cell line in 50% Matrigel (Corning, New York, USA). After tumors reached 4 to 5 mm in diameter, animals received 3 × 10⁹ autologous PBMCs infusion intraperitoneally. Next day they were randomized and treated intratumorally with 1 × 10⁶ VP of either Ad5/3-E2F-d24 or Ad5/3-E2F-d24-hI7 virus. Control animals received intratumoral injections of PBS. Tumors were measured with a digital caliper, and tumor volumes were calculated as (length × width × depth)/2.
x width$^2$/2. Mice received a total of six rounds of virus treatment before they were euthanized on day 16, and their tumors and blood were harvested for subsequent analysis.

**Flow cytometry**

Analysis of immune cells from hamster’s tumor single-cell suspensions was performed using the following cross-reactive antibodies: PE-Cyanine7 anti-mouse CD4, PE anti-rat CD8b, Alexa Fluor 488 polyclonal anti-asialo-GM1, FITC anti-mouse /rat MHC class II (I-EK) (Supplementary table S2).

Analysis of immune cell populations from ex vivo tumor cultures was performed using the following antibodies: V500 anti-human CD4, FITC anti-human CD8, PE-Cy7 anti-human CD69, PE-CF594 anti-human CD127, BV421 anti-human Granzyme B, PerCP-Cyanine5.5 anti-human Perforine, APC-Cyanine7 anti-human CD107a antibodies (Supplementary table S2). Intracellular staining was performed using BD CytoFix/Cytoperm Plus Kit (with BD GolgiPlug) (BD Biosciences, New Jersey, USA), according to manufacturer’s instructions. Samples were stained after Fc blocking using Human TruStain FcX Receptor Blocking Solution (Biolegend, California, USA).

Analysis of immune cells from murine PDX-OvCa tumors was performed using the following antibodies: Alexa Fluor 700 anti-human CD3, V500 anti-human CD4, FITC anti-human CD8, PE-Cy7 anti-human CD69 (Supplementary table S2).

All samples were acquired in duplicates using FACS Aria II cell sorter (BD Biosciences, New Jersey, USA) collecting at least 50,000 events per sample. Data analysis was performed using Flowjo software v10 (Flowjo LLC, BD Biosciences, New Jersey, USA).

**Statistical analysis**

GraphPad Prism v.8.4.2 (GraphPad Software) was used for statistical analysis and graphical representation of the data. The normality of tumor progression data was assessed using Shapiro–Wilk test, and the equality of variances – using Levene’s test. To compare groups in animal experiments, two-way ANOVA with Tukey multiple comparisons test was used. Unpaired t-test was used to compare treated groups, and correlations between variables were investigated using Pearson correlation. Heatmaps for RNAseq data were designed using RStudio.

**Results**

**An oncolytic adenovirus armed with human IL7 is able to deliver the transgene to cancer cells and lyse multiple cancer cell lines**

Previously, we demonstrated the ability of Ad5/3-E2F-d24 viruses to penetrate and replicate in several cancer cell lines. The oncolytic adenovirus coding for human IL7 utilizes the same backbone from adenovirus serotype 5 that carries the fiber knob from serotype 3, has a 24-bp deletion (d24) in the constant region 2 of the E1A gene and the insertion of a tumor-specific E2F promoter upstream the E1A region. Moreover, E1B 19 K gene was deleted to enhance the cytotoxicity of adenovirus by inducing early cell lysis and enhancing progeny release. The human IL7 gene was introduced in the partially deleted E3 gene region, making the transgene expression linked to virus replication (Figure 1a).

The ability of Ad5/3-E2F-d24-hIL7 to infect and lyse cancer cells was evaluated in vitro using several human and hamster cell lines. Human lung and rhabdomyosarcoma cancer cell lines (A549 and RD, respectively), and hamster leiomysarcoma, lung and pancreatic cancer cell lines (DDT1-MF2, HT100 and HapT1, respectively) were infected with different concentrations of Ad5/3-E2F-d24-hIL7; uninfected cells and cells infected with previously described unarmad Ad5/3-E2F-d24 virus were used as controls. Accordingly, the lytic efficacy of Ad5/3-E2F-d24-hIL7 virus was comparable to the unarmad viruses (Figures 1B and 1c). These results demonstrate that the presence of the IL7 transgene does not affect virus oncolytic features.

To assess the ability of the virus to induce transgene expression in cancer cells, A549 cell line was infected with Ad5/3-E2F-d24-hIL7 and culture supernatants were analyzed for the presence of IL7 protein levels. Notably, human cell lines showed higher concentration of IL7 with the maximum amount of 17.5 ng/ml produced by A549 (Figure 1d). Hamster cell line HT100 had the lowest protein level (0.4 ng/ml), while DDT1-MF2 and RD cell lines had similar productivity of around 2.5 ng/ml of IL7 (Figure 1d).

Next, we evaluated the bioactivity of human IL7 produced by the virus. To do this, we incubated IL7-dependent murine cell line 2E8 with several dilutions of A549 supernatant with subsequent cell proliferation measurement. We observed dose-dependent cell proliferation with the better outcome at 1:4 dilution compared to control group (Figure 1e).

To evaluate the suitability of the Syrian hamster animal model for analysis of Ad5/3-E2F-d24-hIL7 in vivo antitumor activity, we first assessed the cross-reactivity of human IL7 in Syrian hamsters. To do this, we stimulated hamster splenocytes with ConA and recombinant human IL7 and observed significantly increased proliferation rate compared to unstimulated cells and ConA alone ($p < .0001$ and $p = .0061$, respectively), while no significant difference was observed between the groups treated with IL7 and IL2 ($p = .6308$) (figure 1f).

Overall, we confirmed that Ad5/3-E2F-d24-hIL7 is capable of killing cancer cells and inducing the expression of bioactive IL7. Moreover, human IL7 is cross-reactive and can be used for in vitro and in vivo studies in Syrian hamsters.

**IL7 oncolytic adenovirus promotes tumor regression in a hamster model of pancreatic cancer**

The in vivo efficacy of Ad5/3-E2F-d24-hIL7 was tested in the immunocompetent Syrian hamster, a preclinical model semi-permissive to adenovirus replication. Pancreatic cancer cell line HapT1 was engrafted subcutaneously to allow heterotopic tumor formation and subsequent intratumoral virus injections (Figure 1g). 15 days after treatment initiation, hamsters in the mock control group had significantly larger tumors when compared to virus-treated animals. Both backbone and IL7 coding virus-treated groups showed a trend for the reduction
of tumor volumes, however IL7 coding virus-treated animals had notably smaller tumors than mock and Ad5/3-E2F-d24-treated animals \((p < .0001 \text{ and } p = .0463, \text{ respectively})\) (Figure 1h). Importantly, no side effects were observed and none of the treatments caused histopathological changes in normal hamster tissues (lungs, hearts, kidneys, livers, and spleens) 55 days after treatments started.

To gain a better understanding of the immunological mechanism of action of the IL7 armed adenovirus, we evaluated the frequency and diversity of tumor-infiltrating immune cells. We observed significantly higher number of CD8b+ T cells \((p = .0077)\) and monocyte/macrophages (Mac-2 + cells) \((p = .0125)\) (Figure 1i) in the IL7 virus treated tumors compared to unarmed virus. Number of CD4 + T cells and Asialo-GM1+ NK cells was higher in IL7 virus-treated group, but not statistically significant, while no difference was observed in the number of MHC class II+ cells. Interestingly, we observed significantly higher number of CD8b+ T cells \((p = .0362)\), MHCII+ cells \((p = .0284)\) and higher number of CD4 + T cells in blood (Supplementary figure S1A). No major differences between virus-treated groups were observed in splenocytes, except higher number of Mac2+ monocytes/macrophages \((p = .0125)\) (Supplementary figure S1B).

Additionally, we measured the expression level of several immune-related genes in tumors harvested from animals. We observed substantial upregulation of canonical T cell activation markers CD25 \((p = .002)\) and CD137 \((p = .0293)\) in IL7 virus-treated group compared to backbone (Figure 1j). IFNγ, Perforin...
and PD1 showed upward trend in IL7 group, however the difference was not significant. No major differences were observed in the level of Granzyme B between virus-treated groups.

In conclusion, we showed that Ad5/3-E2F-d24-hIL7 virus treatment leads to effective in vivo tumor regression and enables the increased frequency of important immune cell subtypes and activation of relevant immune-stimulating factors.

**Oncolytic adenovirus armed with IL7 infects and replicates in patient-derived ex vivo tumor cultures.**

To further investigate the mechanism of action of the oncolytic adenovirus armed with IL7, we shifted toward more clinically relevant ex vivo tumor models. For this, we studied 3 samples of high grade serous carcinoma of fallopian tube (stage IVB), named as HUSOV4, OvCaS and HUSOV5 (Table 1). As expected, cell viability tests showed comparable lytic ability for both the backbone and IL7 encoding virus in all samples: after 3 days of incubation the viability reduced to 70–80% and continued to decrease until day 7 (Figure 2a).

Next, we evaluated the virus copy number in ex vivo tumor samples via quantitative real-time PCR targeting the E4 gene of the adenovirus. Overall, the amount of the viral DNA was comparable between the backbone and IL7 encoding virus across all tested samples (Figure 2b). However, there was clear difference in the total viral copy number between the samples: OvCaS and HUSOV5 produced the highest amount of virus DNA, whereas in HUSOV4 the virus concentration was roughly 100 times lower (Figure 2b).

Finally, we measured the human IL7 concentration in cancer culture supernatants. In all tested samples, we saw an increase in IL7 concentration from day 1 to day 3, however, as expected, the amount of protein was different across the samples. HUSOV4 and HUSOV5 samples had higher amount of IL7 reaching 0.57 and 0.35 pg/ug of total protein respectively, while IL7 concentration in OvCaS sample was at least 3 times lower and reached only 0.13 pg/ug of total protein (Figure 2c).

Overall, this data shows the ability of IL7 coding oncolytic adenovirus to infect, replicate and lyse patient-derived tumor digests, despite the biological differences between the samples.

**Oncolytic adenovirus armed with IL7 creates an immunostimulating local tumor microenvironment**

In order to evaluate the immune status of infected patient-derived ex vivo ovarian cancer samples, we measured the concentration of key immune signaling molecules in the cell culture supernatants 3 days after infection. First, we compared the level of proinflammatory cytokines: IL2, TNFα, IFNγ and IL1b (Figure 3a). All tested samples showed statistically significant increase of IFNγ when infected with IL7 encoding virus compared to uninfected cells and/or backbone virus group (p = 0.087 and 0.0351 for HUSOV4, p = 0.0009 and 0.0011 for OvCaS and p = 0.0065 and 0.0078 for HUSOV5, respectively). When infected with IL7 virus, OvCaS samples also displayed higher expression of IL2 (p = 0.021 and 0.0320, respectively) and TNFα (p = 0.017 and 0.0133, respectively) compared to uninfected cells and mock (Figure 3a). HUSOV4 and HUSOV5 did not exhibit other marked cytokine changes across the different experimental groups. No changes in the level of IL1b were observed in all tested samples. Overall, the level of pooled proinflammatory cytokines in OvCaS and HUSOV5 was notably higher in IL7 virus-treated group compared to other groups (Figure 3b).

Next, we measured the level of anti-inflammatory cytokines: IL4, IL6, IL10 and TGFβ (Figure 3c). Overall, no significant increase of cytokine levels was observed in virus-treated groups compared to uninfected cells. HUSOV4 demonstrated a notable reduction in IL4, IL6 and IL10 concentration, while OvCaS and HUSOV5 had reduced amount of TGFβ upon infection with IL7 encoding virus. The level of pooled anti-inflammatory cytokines was decreased in 2 out of 3 samples (OvCaS and HUSOV5) in cultures infected with the IL7 encoding virus (Figure 3d). The reduction was statistically significant between IL7 encoding virus and mock and backbone in the OvCaS sample (p = 0.048 and 0.0398 respectively) (Figure 3d). Importantly, the IL-7 encoding virus induced the highest prevalence of proinflammatory cytokines over anti-inflammatory ones in all tested ovarian cancer patient samples (Figure 3e).

Overall, these data showed the ability of Ad5/3-E2F-d24-hIL7 to induce the production of signaling molecules for converting the tumor microenvironment toward proinflammation, a status associated with the activation of T cells.

**Table 1. Characteristics of the patient samples used in the study.**

| Patient ID | Age | Gender | Tumor Type               | Diagnosis               | Resection  | Location     |
|------------|-----|--------|--------------------------|-------------------------|------------|--------------|
| HUSOV4     | 79  | F      | Ovarian                  | High grade serous carcinoma St IVB | metastasis | Greater Omentum |
| OvCaS      | 61  | F      | Ovarian                  | High grade serous carcinoma St IVB | metastasis | Greater Omentum |
| HUSOV5     | 76  | F      | Ovarian                  | High grade serous carcinoma St IVB | metastasis | Greater Omentum |
| HUSOV10    | 65  | F      | Ovarian                  | High grade serous carcinoma St IVB | metastasis | Greater Omentum |
| HUSL1U1    | 73  | M      | Lung                     | Adenocarcinoma, pT3N0M0 | primary    | Left lung lower lobe |
| HUSL1U5    | 67  | F      | Lung                     | Adenocarcinoma, T4N0M0 | primary    | Right lung lower lobe |
| HUSHN15    | 81  | F      | Head and Neck            | Squamous cell carcinoma, cT3N1M0 Still grade 2 | primary    | Base of tongue |
| HUSHN17    | 54  | F      | Head and Neck            | Squamous cell carcinoma, T3N3BM0 StVb | primary    | Tongue |
| RCC2       | 52  | F      | Renal Cell               | Clear cell renal cell carcinoma, pT3aN1 | primary    | Left kidney |
Oncolytic adenovirus armed with IL7 enables T cell migration to the tumor site

Besides measuring the levels of cytokines, we measured the level of chemokines in ex vivo infected ovarian cancer samples: CCL2, CCL5, CXCL9, CXCL10. Most notably, virus-treated samples showed remarkable increase in CCL5 and CCL10 production, wherein IL7 encoding virus yielded significantly higher production than the backbone (Figure 3a). HUSOV4 sample did not show any other changes in chemokines concentration across the groups, while OvCaS sample additionally showed upregulation of CCL2 and CXCL9 when treated with IL7 encoding virus. HUSOV5 sample showed notable upregulation of CCL5, CXCL9 and CXCL10 upon infection with IL7 encoding virus.

Since these chemokines are the main attractors for T cells, we next tested whether the change in chemokine concentrations can affect the migration of immune cells in OvCaS and HUSOV5 samples. Indeed, the absolute count of migrated immune cells was significantly higher in both samples treated with IL7 virus compared to mock and backbone (for OvCaS p = 0.0009 and 0.0127, respectively; for HUSOV5 p = 0.0389 and 0.0441, respectively) (Figure 3g).

Moreover, we characterized the populations of migrated cells. In OvCaS treated with Ad5/3-E2F-d24-hIL7 the frequency of migrated CD4+ and CD8+ cells was statistically significantly higher than in mock and Ad5/3-E2F-d24 treated group (for CD4+ cells p = 0.0038 and p < 0.0001, respectively; for CD8+ cells p = 0.0025 and 0.0014, respectively) (Figure 3h). In HUSOV5 treated with IL7 virus the number of CD4+ and CD8+ cells as well as NK cells were significantly higher than in mock and Ad5/3-E2F-d24 treated group (for CD4+ cells p < 0.0001 and 0.0001, respectively; for CD8+ cells p < 0.0001 both; for NK cells p = 0.0090 and 0.0309) (Figure 3h).

Altogether, these data showed the ability of Ad5/3-E2F-d24-hIL7 to induce the production of functional chemokines and the ex vivo recruitment of immune cells (CD4+, CD8+, NK cells).

Oncolytic adenovirus armed with IL7 activates infiltrating CD4+ and CD8+ T cells in multiple cancers in a dose-dependent manner

To evaluate the effect of Ad5/3-E2F-d24-hIL7 on tumor-infiltrating lymphocytes, we first verified the expression level of activation and cytotoxic markers separately on CD4+ and CD8+ cells from HUSOV4, OvCaS and HUSOV5 ex vivo tumor cultures treated with the oncolytic adenoviruses via flow cytometry. Upon infection with the IL7 encoding virus, HUSOV4 and HUSOV5 cultures showed a significant increase in the amount of CD69+ CD4+ T cells (for HUSOV4 p = 0.0082 and 0.0094, respectively; for HUSOV5 p = 0.0020 and 0.0075, respectively) (Figure 4a) and CD69+ CD8+ T cells compared to mock and backbone groups (for HUSOV4 p = 0.0031 and 0.0013, respectively; for HUSOV5 p = 0.0116 and 0.0059, respectively) (Figure 4f). OvCaS sample showed similar trend, but the difference was not significant. Moreover, we observed higher frequency of IFNγ +CD4+ cells (Figure 4b) as well as IFNγ+CD8+ cells (Figure 4g) in HUSOV4 and HUSOV5 cultures treated with Ad5/3-E2F-d24-hIL7 compared to mock and Ad5/3-E2F-d24 groups.

On the transcriptome level we observed substantial upregulation of activation-associated genes, such as HBEFG, MAP3K8, OSM, TNFSF8 (CD40LG), FLT3LG, ALOX5, TXK, IRF4, in IL7 virus treated samples, however, CD4+ cells showed higher number of markers compared to CD8+ cells (Figure 4e and Figure 4j, respectively). Moreover, the inflammation-associated genes (IL2RB, IL18R1, CEACAM1, CREM, FRMD4B) were also upregulated in IL7 virus treated group compared to mock.
Next, we evaluated the changes in the proportion of cytotoxic T cells expressing Perforin (Perf), Granzyme B (GzmB) and TNFα – potent cytotoxic agents. In contrast to mock and backbone virus, in HUSOV4 and HUSOV5 cultures treated with IL7 encoding virus, we observed a notable increase of GzmB+ T cells, both CD4+ cells (Figure 4c) and CD8+ cells (Figure 4h) and an upward trend in TNFα+ CD4+ T cells (Figure 4d). All 3 cultures treated with Ad5/3-E2F-d24-hIL7 also showed an upward trend in frequency of Perf+CD8+ cells, however, only in HUSOV5 the difference was statistically significant compared to mock (p = .0002) and backbone group (p = .0052) (Figure 4i).

Interestingly, on transcriptome level we observed an upregulation of many cytotoxic markers in CD4+ cells (GZMB, GZMH, PRF1, TNF, NKG7, CCR2, PRDM1), but only three in CD8+ cells (LTA, LTB, NCR3). Notably, in contrast with CD4+ cells, we observed increased regulatory transcription factors FOXP3, BACH2 and MYB2 expression in CD8+ cells. Additionally, both CD4+ cells and CD8+ cells showed upregulation of survival-associated genes BCL2, PIM1 and PDE4B.

Moreover, we verified our previous observation of higher number of migrated cells in the samples treated with IL7 virus by the upregulation of migration-associated genes ADAM19, DPP4, ITGA4, CCR5, SOS1 and MYO1G in CD4+ T cells and ADAM19, FURIN and DPP4 in CD8+ cells (Figure 4e and Figure 4j, respectively).

To understand whether Ad5/3-E2F-d24-hIL7 treatment is cancer-specific, we additionally tested one more ovarian cancer sample and 5 patient-derived samples of different origin: two lung cancer samples HUSL1 and HUSL5, two head and neck cancer samples HUSH15 and HUSH17 and one renal cell carcinoma sample RCC2 (Table 1). Overall, we observed increased amount of GzmB+CD4+ cells in all samples treated with IL7 encoding virus (Figure 5a) and did not find any correlation between the cell frequencies and IL7 concentration (Figure 5e). However, number of IFNγ+CD4+, IFNγ+CD8+ and CD69+ CD8+ was different across the samples (Figure 5b, 5c and 5d, respectively) and statistically significant correlated with IL7 concentration in the sample (Figure 5f, 5g and 5h, respectively).
Overall, this data suggests the ability of Ad5/3-E2F-d24-hIL7 to activate infiltrating CD4+ cells and, to a lesser extent, CD8+ cells and to increase the proportion of cytotoxic immune cells in a dose-dependent manner.

**Activated infiltrating CD4+ and CD8+ T cells are able to re-express IL7 receptor**

We evaluated the presence of IL7 receptor chain α (IL7Ra) on the surface of the T cells. In both CD4+ and CD8+ cells from Ad5/3-E2F-d24-hIL7 treated cancer cultures we observed the upregulation of CISH and SOCS2 genes (Figure 4e and Figure 4g, respectively), which are involved in the receptor internalization and degradation (Figure 5i). This data was supported by flow cytometry results showing a decrease in IL7Ra+ cells on day 1 upon infection on both CD4+ (Figure 5j) and CD8+ cells (Figure 5k). However, we observed gradual increase in IL7Ra+CD4+ and ILRa+CD8+ cells frequency until day 7 (Figure 5j and 5k, respectively). Interestingly, on day 7 number of GzmB+IL7Ra+CD4+ cells and CD69+IL7Ra+CD4+ cells, which can be considered as previously activated cells, was higher than on days 1 and 3 (Figure 5i).

This data suggests that infiltrating CD4+ and CD8+ cells are able to re-express IL7 receptor after treatment with Ad5/3-E2F-d24-hIL7, and at least CD4+ remain activated and exhibit cytotoxic phenotype.

**IL7 oncolytic adenovirus promotes tumor regression in a patient-derived xenograft (PDX) model via proliferation and activation of immune cells**

The in vivo efficacy of Ad5/3-E2F-d24-hIL7 was additionally tested in more translationally relevant PDX model. Additionally, we compared two available immunodeficient models – NOG and NOG-IL2, the latter expressing human IL2 for improving reconstitution of patient matched immune cells following transfer.

PDX-OvCa cell line was engrafted subcutaneously into mice (5 animals per group) with subsequent intraperitoneal infusion of autologous PBMCs followed by intratumoral virus injections (Figure 6a). After 6 rounds of treatment, NOG mice in the IL7 virus-treated group had significantly smaller tumors when compared to mock group (p < .0001) and unvired group (p = .0001) (Figure 6b). Next, we evaluated the frequency and diversity of tumor-infiltrating and circulating immune cells. We observed significant higher number of CD4 + T cells (p = .0364), and CD8+ tumor-infiltrating cells (p = .0497) (Figure 6c) in the IL7 virus treated tumors compared to mock. Moreover, we observed a positive trend in immune cell frequency between unvired virus-treated group and IL7 virus-treated group, although the difference was not significant. The proportion of activated CD69+ CD4+ cells was similar across all groups, however, IL7 virus treated animals
had more activated CD69+ CD8+ cells compared to mock ($p = .0455$) and to unarmad virus-treated mice ($p = .0695$) (Figure 6d). Additionally, measuring the number of immune cells circulating in the blood, we found significant increase of CD4+ cell in animals, treated with IL7 armed virus compared to mock ($p = .0007$) and backbone group ($p = .0025$), while no clear difference was observed for CD8+ cells (Figure 6e).

NOG-IL2 mice showed similar trend to the tumor reduction, although more moderate: in the IL7 virus-treated group tumors were significantly smaller when compared to mock group ($p < .0001$) and unarmed virus ($p = .0029$) (Figure 6f). We observed higher number of CD4 + T cells ($p = .016$) and activated CD69+ CD4+ cells ($p < .0001$) in tumors, while the proportion of CD8+ cells and activated CD69+ CD8+ cells remained similar across all groups (Figure 6g and 6h, respectively). We also did not find any difference in the number of circulating immune cells (Figure 6i).

In conclusion, we showed the ability of Ad5/3-E2F-d24-hIL7 virus to cause tumor regression via improved immune cells proliferation and infiltration in two translationally relevant ovarian PDX models.

**Discussion**

IL7 is well known as a homeostatic cytokine enabling T cell proliferation in lymphopenic hosts. Subcutaneous administration of recombinant glycosylated hIL7 (CYT107, RevImmune,
France) showed significant expansion of circulating T cells and mild to moderate adverse events in patients with metastatic melanoma and sarcoma, breast cancer, and prostate cancer. Although these studies were not designed to evaluate anti-tumor activity, one subject with central nervous system hemangiopericytoma and abdominal metastases had a substantial improvement of abdominal pain and a 20% reduction in tumor size at 3 months. The abdominal disease remained stable for 9 months after rhIL7 therapy. Later on, Merchant et al. showed the efficacy of adjuvant IL7 therapy to improve survival in patients with metastatic pediatric sarcoma, although treatment efficacy was associated with histologic type of tumor. This clinical data demonstrates that IL7 therapy continues to be an attractive anti-cancer approach, however its efficacy is limited, most likely due to insufficient IL7 concentration within the tumor.

In this study we created an oncolytic adenovirus armed with human IL7 allowing transgene delivery and expression at the tumor site. In vitro data showed the ability of the virus to lyse...
several types of human and hamster cancer cell lines as well as cause the production of bioactive human IL7. Interestingly, the concentration of IL7 significantly varied among the cell lines, most likely due to differences in cell permissiveness, virus replication time and number of virus entry receptors.

Our preclinical data highlights the benefits of intratumorally expressed human IL7. We confirmed that oncolytic adenovirus Ad5/3-E2F-d24-hIL7 stimulates T cells and improves their infiltration leading to better tumor control in three clinically relevant animal models. We observed higher number of tumor-infilitrating CD4+ and CD8+ cells in both the immunocompetent pancreatic cancer hamster model and humanized ovarian cancer murine PDX model, as well as upregulation of T cells activation markers, such CD69 and CD25. As a result, animals treated with the virus armed with IL7 showed significant decrease in tumor size compared to the animals treated with unarmed virus.

Moreover, comparing two available immunocompromised models NOG and NOG-IL2 (Taconic) we observed more moderate immune response difference between the virus-treated groups in the latter. Most likely, overexpression of human IL2 can generally improve virotherapy by additional activation of immune cells, however, as expected, high concentration of IL2 leads to the adverse events and all animals regardless of the group appeared unhealthy 16 days after PBMCs engraftment. Interestingly, despite smaller tumors, the frequency of infiltrating CD4+ and CD8 + T cells was not significantly different in virus treated groups, even if there was a positive trend in cell number in tumors, treated with Ad5/3-3-E2F-d24-hIL7. This can be explained by more active cancer cells lysis in IL7 virus treated group, and therefore lowered replication of the virus and reduced transgene concentration, making the difference between the viruses elusive.

Since the reagents and assays for hamsters and immunodeficient animals are limited, and there is a point in studying the hypothesis from a translational perspective, we continued with ex vivo samples obtained from ovarian cancer patients. We first focused on the samples of high-grade serous carcinoma, which make up the majority of epithelial ovarian cancer cases. Most serious carcinomas are diagnosed at stage III (51%) or IV (29%), for which the 5-year cause-specific survival is 42% and 26%, respectively. Standard therapy includes surgery followed by platinum-based chemotherapy, however, to date, several immunotherapy approaches have been considered as a potential ovarian cancer treatment. The reason might be that epithelial ovarian cancers usually have high frequency of T cell infiltrates, but also high percentage of immunosuppressive cells, such as regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). Thus, converting tumor microenvironment toward immunostimulatory one with an IL7 coding virus might be required to improve patients’ response rate and overall survival.

In this study, we established 3 ex vivo ovarian cancer cultures and infected them with either unarmed or IL7 armed viruses. We observed significant decrease in cell viability in all samples upon infection showing that Ad5/3-E2F-d24-hIL7 is able to infect and lyse cancer cells presented in tumors. Interestingly, the concentration of IL7 in the supernatants was different between the samples. The reason might lie in the different proportion and initial viability of cancer cells in the samples, which are necessary for virus dissemination and replication. In general, it is important to mention, that the observed variations between the samples were expected for patient tumors due to individual set of mutations and tumor heterogeneity, regarding proportions of cancer, stromal and immune cells, as well as different frequency of immune cell populations.

The analysis of the tumor microenvironment showed a clear shift toward proinflammatory signaling in ex vivo patient samples infected with Ad5/3-E2F-d24-hIL7, particularly, increased IFNγ production, which, in turn, stimulates expression of Ccl5, Cxcl9 and Cxcl10 – key chemokines involved in the recruitment of T cells and NK cells. Indeed, we observed higher number of CD4+ and CD8+ migrated cells when used supernatants obtained after infection with IL7 armed virus. Transcriptional analysis showed upregulation of several migration-related genes in CD4+ cells – CCR5, DPP4, ITGA4, MYO1G. Interestingly, we observed significant upregulation of ADAM19 gene in both CD4+ and CD8+ T cell, however, the role of this particular protein in immune cells is still unclear. ADAM proteins are membrane disintegrins and metalloproteinases, which convert nearby membrane-anchored cytokine precursors, cytokine receptors, Notch receptors, phagocytic receptors or cell adhesion molecules into soluble bioactive mediators. In T cells, ADAMs can be involved in cell development and activation via cleavage of negative regulatory proteins, such as LAG3, and regulate cell migration not only due to the proteolytic activity of ADAMs on the T cells themselves, but also due to the protease activity on the tissue cells serving as substrate of cell migration. Nevertheless, additional experiments are needed to understand the role of ADAM19 in T cells activation and migration upon Ad5/3-E2F-d24-hIL7 infection.

Further study of ex vivo patient samples showed the ability of the virus armed with IL7 to increase the number of polyfunctional cytotoxic CD4 + T cells expressing serine protease Granzyme B in two samples out of three. This finding was verified by RNaseq data showing higher expression of cytotoxic markers GZBM, GZMH, NKG7, PRF1 and TNF in the samples treated with Ad5/3-E2F-d24-hIL7. Importantly, we didn’t observe FOXP3 upregulation in CD4 + T cells, but decreased expression of BCL6 and higher expression of PRDM1, encoding the transcriptional repressor Blimp-1, which are involved in CD4+ cells differentiation toward cytotoxic phenotype. CD8 + T cells showed moderate activation capacity, in contrast to CD4+ cells. Despite similar signature, the number of differentially expressed genes upon IL7 virus infection in CD8+ cells was lower. Moreover, due to higher frequency of transcriptional factors FOXP3, BACH2 and MYBL1 transcripts in Ad5/3-E2F-d24-hIL7 treated group, CD8+ cells exhibited a regulatory phenotype rather than an effector phenotype. CD8 + T regs is a very small population of regulatory immune cells which is not well described yet. One study claimed these cells only mildly suppress T cell proliferation and IFN-γ production, compared to classic CD4+ CD25+ FoxP3 + T regs. Thus, we cannot say if the upregulation of FoxP3 in CD8+ cells correlates with severe immunosuppression.
Further, we analyzed more patient derived samples of different origin: lung, head and neck and renal cell cancer. As expected, we observed increased number of cytotoxic GzmB+CD4+ cells in all samples, however, the number of IFNγ+ CD4+ and CD8+ cells was different among the samples. As we described earlier, the concentration of IL7 may differ depending on the number of cancer cells in the sample, and we found a positive correlation between IL7 concentration and number of activated IFNγ+ T cells. Interestingly, we did not find any other correlations, e.g. cancer type, sample viability or amount of immune cells. Moreover, most likely CD4+ cells outcompete CD8+ cells when the IL7 concentration is limited, which lead to lesser activation of CD8+ cells.

Another important aspect of IL7 stimulation is the re-expression of IL7 receptor a chain (IL7Ra) on the surface of T cells. Upon activation, naïve T cells rapidly downregulate the receptor due to expression of SOCS proteins, which are involved in receptor internalization and degradation, thus becoming effector functions. However, CD4+ and CD8+ cells can steadily re-express IL7Ra exhibiting memory cells phenotype, but both continue to be dependent on IL7 for their long-term survival. We observed IL7Ra re-expression on these cells on day 7 after viral infection, while the frequency of IL7Ra+CD4+ cells were higher. Moreover, we did not observe any proliferation of CD4+ and the population of IL7Ra+CD4+ showed significant increase in Granzyme B and CD69 expression on day 7, which can be further explained by re-expression of the receptor by already activated cells. Altogether, our data shows the importance of high IL7 expression level for T cell priming, in other words, high Ad5/3-E2F-d24-hIL7 virus concentrations and/or repeated treatments are potentially beneficial for immune cell activation and therefore for tumor cell elimination.

In conclusion, our data demonstrates the ability of the new oncolytic adenovirus armed with IL7 to stimulate CD4 + T cells, and to a lesser extent CD8+ T cells, and improve their recruitment to the tumor site. This allowed for higher proportion of tumor-infiltrating lymphocytes and better tumor control in immunocompetent hamster pancreatic cancer and immunocompromised murine ovarian cancer models. The mechanism of action of Ad5/3-E2F-d24-hIL7 can be explained through improved activation and survival of immune cells as well as generation of cytotoxic CD4+ cells.

However, we believe it is possible to achieve even better antitumor and immunostimulatory response from the Ad5/3-E2F-d24-hIL7 treatment. Due to current model limitations, like semi-permissiveness of hamster cells, limited reagents for studies, immunodeficient models lacking competent immune system or short observation time of ex vivo samples, we could evaluate only early activated T cells, thus, additional studies are needed to elucidate the impact of TILT-517 on other lymphoid and myeloid cells. For example, several murine models were reported to be semi-permissive for the adenoviruses and support the transgenes expression in the tumor microenvironment. Thus, using fully immunocompetent mice might be a reasonable solution to collect the data from B cells, NK cell, T regs and other suppressive cells, such as myeloid-derived suppressive cells and M2 macrophages. Of critical importance is to evaluate effector and central memory cells and, therefore, the generation of immunological memory and, as a result, better survival, and reduced probability of tumor relapse. Moreover, murine models make possible the depletion study which is essential for the understanding of main cell populations responsible for the anti-tumor response.

Additionally, we believe the combination of Ad5/3-E2F-d24-hIL7 with immune checkpoint inhibitors (ICIs) is a promising approach to increase the potency of the latter. Based on our data, TILT-517 is able to convert tumor microenvironment into immunostimulatory one and attract immune cells, thus improving the efficacy of ICIs which tend to work only in “hot” tumors. An important aspect is the ability of IL7 to prevent T cells exhaustion by decreasing the expression of PD-1 receptor on the surface of the cells. Thus, the combination with apD-1 antibody might be a good strategy to get better therapeutic outcome in tumor types showing impaired T cell function, such as pancreatic or metastatic renal cell cancer.

Another interesting question regarding combination of apD-1 and Ad5/3-E2F-d24-hIL7 is the possible better antitumor response in non-injected tumors. Recent studies showed better antitumor response in non-injected tumors in animals treated with oncolytic adenovirus in combination with apD-1; however, in the context of IL7-induced immune memory cell formation, the abscopal effect might be additionally improved via combination of apD-1 and Ad5/3-E2F-d24-hIL7.

Overall, based on our data, arming of adenoviruses with IL7 is appealing and this approach can be translated to the clinic, however, additional studies should be performed to evaluate full potential of the novel virus.

**Acknowledgments**

We thank Minna Oksanen and Riikka Kalliokoski for expert experimental and administrative assistance and Marijukka Anttila for her help with histopathological evaluation of the tissue samples. We also thank Dmitriy Bychkov, Annabrita Schoonenberg and FIMM digital microscopy and molecular pathology unit (University of Helsinki, Helsinki, Finland), Laboratory Animal Center (LAC, University of Helsinki, Helsinki, Finland) and Biomedical Flow Cytometry Unit (University of Helsinki, Helsinki, Finland). Additionally, we thank Taconic Biosciences GmbH (Leverkusen, Germany) for the help with animal models. Open access funded by the Helsinki University Library (University of Helsinki, Finland).

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

This study was supported by Doctoral programme in clinical research (University of Helsinki), Jane and Aatos Erkko Foundation, HUCH Research Funds (VTR), Finnish Cancer Organizations, Novo Nordisk Foundation, Päiviikki and Sakari Sohlsberg Foundation and TILT Biotherapeutics Ltd. This study received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 813453.

**ORCID**

Akseli Hemminki http://orcid.org/0000-0001-7103-8530
Ethics statement

All animal experiments described in the paper were approved by the Provincial Government of Southern Finland and the Experimental Animal Committee of the University of Helsinki (license number EASVI/12559/2021).

Cancer samples were collected from the patients undergoing surgical resection at the Helsinki University Central Hospital (HUS, Helsinki, Finland). Sample collection was approved by HUS Operatives Ethics Committee (permit numbers HUS/850/2017, HUS/3360/2019 and HUS/259/2021) and the patients gave their written consent.

Authors’ contributions

- TVK, JC, DCAQ, JMS, RH, CH, IGN and AH designed the experiments;
- TVK, JC, DCAQ, JMS, SB, SP, SGVK and VA conducted the experiments;
- KA, LB, JR, II, KB, MR, OH, AR, AK and JT collected the patient samples;
- TVK, JC and AK analyzed the results;
- All the authors contributed to writing and reviewing the manuscript.

References

1. Fyfe G, Fisher RI, Rosenberg SA, Szol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688–96. doi:10.1002/jco.16113.3.688.

2. Golomb HM, Ratain MJ, Rick D, Daly K. Interferon treatment for hairy cell leukemia: an update on a cohort of 69 patients treated from 1983-1986. Leukemia. 1992 Nov;6(11):1177–1180.

3. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 1998 Aug; 83(4):797–805. PMID: 9708948.

4. Kirkwood JM, Goldhirsh A, Barylk E, Borden E. Quality-of-life adjusted survival analysis of interferon alpha-2b adjuvant treatment of high-risk cutaneous melanoma: an eastern cooperative oncology Group study. J Clin Oncol. 1996;14:2666–2673. doi:10.1002/jco.16114.11.666.

5. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alpha-2b adjuvant therapy of high risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684. J Clin Oncol. 1996;14:7–17. doi:10.1002/jco.16114.1.7.

6. Webb LM, Foxwell BM, Feldmann M. Putative role for interleukin-7 in the maintenance of the recirculating naive CD4 T-cell pool. Immunology. 1999 Nov;98(3):400–405. doi:10.1046/j.1365-2567.1999.00906.x.

7. Sportès C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, Fleisher TAKrumlauf MC, Babb RB, Chow CK, Fry TJ, Engels J, Buffet R, Morre M, Amato RJ, Venzon DJ, Kornold R, Pecora A, Gress RE, Mackall CL. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med. 2008 Jul 205(7):1701–1714. doi:10.1084/jem.20071681.

8. Rosenberg SA, Sportès C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwartz SL, Stetler-Stevenson M, Morton KE, Mavroukakis SA, Morre M, Buffet R, Mackall CL, Gress RE. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother. 2006;29(3):313–319. doi:10.1097/01.jit.0000210386.55951.c2.

9. Heninger AK, Theil A, Wilhelm C, Petzold C, Huebel N, Kretschmer K, Bonifacio E, Monti P. IL-7 abrogates suppressive activity of human CD4+CD25+FOXP3+ regulatory T cells and allows expansion of alloreactive and autoreactive T cells. J Immunol. 2012 Dec 15;189(12):5649–5658. doi:10.4049/jimmunol.1201286.

10. Pellegrini M, Calazasca T, Elford AR, Shahinian A, Lin AE, Dissanyake D, Dhanjil S, Nguyen LT, Gronski MA, Morre M, et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med. 2009 Jul;15(7):819. doi:10.1038/nm0709-819b.

11. Koyas A, Tucer S, Kayhan M, Savas AC, Akdemir I, Cеки C. Interleukin-7 protects CD8+ T cells from adenosine-mediated immunosuppression. Sci Signal. 2021 Mar 16;14:674. doi:10.1126/scisignal.abl1269.

12. Sportès C, RR B, Krumlauf MC, FT H, SM S, CK C, MR B, TA F, Noel P, Maric I, et al. Phase I study of rhIL7 administration in subjects with refractory malignancy. Clin Cancer Res. 2010 Jan 15;16(2):727–735. doi:10.1158/1078-0432.CCR-09-1303.

13. Trédan O, Ménétrier-Caux C, Ray-Coquard I, Garin G, Crozet C, Verronèse E, Bachelot T, Rebattu P, Heuleud PE, Cassier P, et al. ELYPE7-1: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. Ann Oncol. 2018 Feb;29(2):523. doi:10.1093/annonc/mdx058.

14. Lee SW, Choi D, Heo M, Shin EC, Park SH, Kim SJ, Oh YK, Lee BH, Yang SH, Sung YC, et al. IL-7-hypFc, a long-acting IL-7, increased absolute lymphocyte count in healthy subjects. Clin Transl Sci. 2020 Nov;13(6):1161–1169. doi:10.1111.cts.12800.

15. Markley JC, Sadelain M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood. 2010 Apr; 29:115 (17):3508–3519. doi:10.1182/blood-2009-09-241398.

16. Miller PW, Sharma S, Stolina M, Butterfield LH, Luo J, Lin Y, Dohadwala M, Batra RK, Wu L, Economou JS, et al. Intratumoral administration of adenosil interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther. 2000 Jan 11;11(1):53–65. doi:10.1089/10601120030016157.

17. Nakao S, Arai Y, Tasaki M, Yamashita M, Murakami R, Kawate T, Amino N, Nakatake M, Kuroasaki H, Mori M, et al. Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade. Sci Transl Med. 2020 Jan 15;12(526):eaax7997. doi:10.1126/scitranslmed.eaax7997.

18. Huang J, Zheng M, Zhang Z, Tang X, Chen Y, Peng A, Peng X, Tong A, Zhou L. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma. Cancer Immunol Immunother. 2021 Sep;70(9):2435–2465. doi:10.1007/s00262-021-02856-0.

19. Havunen R, Siurala M, Sorsa S, Grönberg-Vähä-Koskela S, Behr M, Tähtinen S, Santos JM, Karel M, Rusamen J, Nettelbeck DM, et al. Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable successful adoptive cellular therapy. Mol Ther Oncolytics. 2016 Dec 31;4:77–86. doi:10.1016/j.omto.2016.12.004.

20. Sharan SK, Thomason LC, Kuznetsov SG, Court DL. Recombining: a homologous recombination-based method of genetic engineering. Nat Protoc. 2009;4(2):206–223. doi:10.1038/nprot.2008.227.

21. Lock M, Korn M, Wilson J, Sena-Esteves M, Gao G. Measuring the infectious titer of recombinant adenovirus using tissue culture infection dose 50% (tcid50) end-point dilution and quantitative polymerase chain reaction (qPCR). Cold Spring Harb Protoc. 2019 Aug 1;2019:8. doi:10.1101/pdb.prot095562.

22. Santos JM, Heinio C, Cervera-Carrasco V, Quixabeira DCA, Siurala M, Havunen R, Butzow R, Zafar S, de Grujil T, Lassus H, et al. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity. J Immunother Cancer. 2020 Jan;8(1):e001888. doi:10.1136/jitc-2019-001888.
